Biosimilar Insulins Promise Patients New Choices, But Competition Is Still Lacking
Spending on insulin has tripled over the past decade, topping $22 billion in 2022. The inflation-adjusted cost of insulin increased 24% from 2017 to 2022. New lower-cost insulin options are becoming available to more Americans with diabetes. Eli Lilly, Novo Nordisk, and Sanofi have announced price cuts and out-of-pocket cost caps for insulin, with the…